NRSG 3100 Units 10-11
enoxaparin (Lovenox) considerations - ANS-more money than heparin; lower molecular weight
heparin; subQ; watch for abnormal bleeding; epidural or spinal hematoma
enoxaparin (Lovenox) classification - ANS-anticoagulant
Heparin considerations - ANS-not a clot buster, prevents clots and prevents from growing;
ALWAYS run on a pump; #1 med for acute clotting disorders; made from animal products; safe
in pregnancy
Heparin adverse effects - ANS-up to 30% of patients get heparin induced thrombocytopenia
(HIT), do not give with spinal block or epidural
What lab needs to be monitored when giving Heparin - ANS-PTT- therapeutic 50-80
Heparin classification - ANS-anticoagulant
Heparin's antidote - ANS-protamine sulfate
abciximab (ReoPro) classification - ANS-antiplatelet agent
abciximab (ReoPro) treats - ANS-prvent thrombotic event in acute coronary syndrome;
decrease platelet function in 2 hours and lasts up to 10 days
abciximab (ReoPro) adverse effects - ANS-major bleeds in 10% of patients (starts most often at
arterial or venous access site); report unusual bleeding or if bleeding lasts longer than 15
minutes
Do not give abciximab (ReoPro) to patients with - ANS-active bleeding, recent surgery or
trauma, and thrombocytopenia
abciximab (ReoPro) antidote - ANS-no antidote; can give platelets
eptifibatide (Integrilin) classification - ANS-antiplatelet agent
eptifibatide (Intergrilin) treats - ANS-prevent clots in acute coronary syndrome
eptifibatide (integrilin) considerations - ANS-rapidly reversible; 24 hour duration; giving platelets
won't help; primary excretion is kidneys (use caution in renal impairment); commonly given with
aspirin or heparin
, eptifibatide (integrilin) adverse effects - ANS-bleeding at access site is the most common
alteplase (Activase) classification - ANS-thrombolytic
retaplase (Retavase) classification - ANS-thrombolytic
streptokinase (Streptase) classification - ANS-thrombolytic
tenecteplase (TNKase) classification - ANS-thrombolytic
aminocaproic acid (Amicar) classification - ANS-hemostatic/antifibrynolytic
mannitol (Osmitrol) classification - ANS-osmotic diuretic for ICP
mannitol (Osmitrol) adverse effects - ANS-electrolyte imbalances, potassium and sodicum
increase or decrease, hypovolemia and dehydration
mannitol (Osmitrol) treats - ANS-increases urine output in renal failure, ICP-pulls fluid from
extravascular spaces; decreases ICP in head trauma; can be used to speed up nephrotic drugs
like cisplatin; used as a sweetener
aminocaproic acid (Amicar) treats - ANS-aplastic anemia, hepatic cirrhosis, post-op cardiac
surgery; action opposite of anticoags; prevents fibrin from disolving
aminocaproic acid (Amicar) adverse effects - ANS-rapid IV=decreased blood pressure and
heart rate, rhabdomyolysis
do not give aminocaproic acid (Amicar) with - ANS-thrombolytics (antagonizes),
hypercoagulation with estrogen and oral contraceptives, DIC, use with caution in renal
impairment
alteplase (Activase) treats - ANS-drug of choice for thrombotic stroke and central line clots; MI;
faster onset than alteplase
alteplase (Activase) adverse effects - ANS-bleeding (catheter access, needle puncture sites or
internally), any abnormal bleeding should be reported
when not to give alteplase (Activase) - ANS-if patient has had a stroke within the last 3 months,
recent trauma or surggery, severe bleeding, HTN, warfarin (INR >1.7, PT>15), with
anticoagulants, antiplatelets, NSAIDS, or aspiriine
antidote for alteplase (Activase) - ANS-no antidote
enoxaparin (Lovenox) considerations - ANS-more money than heparin; lower molecular weight
heparin; subQ; watch for abnormal bleeding; epidural or spinal hematoma
enoxaparin (Lovenox) classification - ANS-anticoagulant
Heparin considerations - ANS-not a clot buster, prevents clots and prevents from growing;
ALWAYS run on a pump; #1 med for acute clotting disorders; made from animal products; safe
in pregnancy
Heparin adverse effects - ANS-up to 30% of patients get heparin induced thrombocytopenia
(HIT), do not give with spinal block or epidural
What lab needs to be monitored when giving Heparin - ANS-PTT- therapeutic 50-80
Heparin classification - ANS-anticoagulant
Heparin's antidote - ANS-protamine sulfate
abciximab (ReoPro) classification - ANS-antiplatelet agent
abciximab (ReoPro) treats - ANS-prvent thrombotic event in acute coronary syndrome;
decrease platelet function in 2 hours and lasts up to 10 days
abciximab (ReoPro) adverse effects - ANS-major bleeds in 10% of patients (starts most often at
arterial or venous access site); report unusual bleeding or if bleeding lasts longer than 15
minutes
Do not give abciximab (ReoPro) to patients with - ANS-active bleeding, recent surgery or
trauma, and thrombocytopenia
abciximab (ReoPro) antidote - ANS-no antidote; can give platelets
eptifibatide (Integrilin) classification - ANS-antiplatelet agent
eptifibatide (Intergrilin) treats - ANS-prevent clots in acute coronary syndrome
eptifibatide (integrilin) considerations - ANS-rapidly reversible; 24 hour duration; giving platelets
won't help; primary excretion is kidneys (use caution in renal impairment); commonly given with
aspirin or heparin
, eptifibatide (integrilin) adverse effects - ANS-bleeding at access site is the most common
alteplase (Activase) classification - ANS-thrombolytic
retaplase (Retavase) classification - ANS-thrombolytic
streptokinase (Streptase) classification - ANS-thrombolytic
tenecteplase (TNKase) classification - ANS-thrombolytic
aminocaproic acid (Amicar) classification - ANS-hemostatic/antifibrynolytic
mannitol (Osmitrol) classification - ANS-osmotic diuretic for ICP
mannitol (Osmitrol) adverse effects - ANS-electrolyte imbalances, potassium and sodicum
increase or decrease, hypovolemia and dehydration
mannitol (Osmitrol) treats - ANS-increases urine output in renal failure, ICP-pulls fluid from
extravascular spaces; decreases ICP in head trauma; can be used to speed up nephrotic drugs
like cisplatin; used as a sweetener
aminocaproic acid (Amicar) treats - ANS-aplastic anemia, hepatic cirrhosis, post-op cardiac
surgery; action opposite of anticoags; prevents fibrin from disolving
aminocaproic acid (Amicar) adverse effects - ANS-rapid IV=decreased blood pressure and
heart rate, rhabdomyolysis
do not give aminocaproic acid (Amicar) with - ANS-thrombolytics (antagonizes),
hypercoagulation with estrogen and oral contraceptives, DIC, use with caution in renal
impairment
alteplase (Activase) treats - ANS-drug of choice for thrombotic stroke and central line clots; MI;
faster onset than alteplase
alteplase (Activase) adverse effects - ANS-bleeding (catheter access, needle puncture sites or
internally), any abnormal bleeding should be reported
when not to give alteplase (Activase) - ANS-if patient has had a stroke within the last 3 months,
recent trauma or surggery, severe bleeding, HTN, warfarin (INR >1.7, PT>15), with
anticoagulants, antiplatelets, NSAIDS, or aspiriine
antidote for alteplase (Activase) - ANS-no antidote
